Clinical characteristics of women with endometrial hyperplasia
DOI: 10.32364/2618-8430-2021-4-2-124-129
K.K. Salamova1, L.V. Saprykina1, A.M. Ramazanova1, Z.T. Mil’dzikhova2, Е.В. Stolyarova1
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Aim: to describe clinical characteristics of women with endometrial hyperplasia.
Patients and Methods: this retrospective single-center study enrolled 86 women who underwent hysteroscopic curettage (with subsequent histology) on the basis of complaints and ultrasound. All women were divided into three groups. Group 1 included 30 women with endometrial hyperplasia (EH). Group 2 included 30 women with endometrial polyps (EP). Group 3 included 26 healthy women without any endometrium conditions (control group). Somatic status, obstetric gynecologic anamnesis, and comorbidities were evaluated.
Results: in women with EH, heavy periods were 2.37- and 2.6-times more common than in groups 2 and 3 (p<0.05) while the rate of other abnormal uterine bleedings was 7.06- and 6.06-times higher, respectively (p<0.05). In women with EH, anemia was diagnosed 4- and 5.2-times more common than in groups 2 (p<0.05) and 3 (p<0.05), respectively. In group 2, inflammatory cervical and vaginal conditions were 3.98- and 3.46-times more common than in group 1 (p<0.05) and group 3 (p>0.05). The occurrence of endocrine disorders in g roup 1 was 4.49- and 3.9-times higher than in group 2 and 3, respectively (p<0.05). Anamnestic thrombosis, strokes, and migraines were reported only in women with EH.
Conclusions: prevention of endometrium conditions entails both early detection and control over ovulation and management of endocrine disorders and treatment of genital tract inflammation. When managing women with uterine fibroids and adenomyosis and anamnestic thrombosis, a doctor should be vigilant about EH.
Keywords: endometrial hyperplasia, endometrial polyp, inflammation, hyperplastic conditions, uterus, thrombosis.
For citation: Salamova K.K., Saprykina L.V., Ramazanova A.M. et al. Clinical characteristics of women with endometrial hyperplasia. Russian Journal of Woman and Child Health. 2021;4(2):124–129. DOI: 10.32364/2618-8430-2021-4-2-124-129.
About the authors:
Kamilla K. Salamova — postgraduate student of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-1137-5492.
Lyudmila V. Saprykina — Cand. of Sci. (Med.), assistant of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-2931-0956.
Alena M. Ramazanova — postgraduate student of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-0927-8562.
Zarina T. Mildzikhova — student of the 6th course of the Medical Faculty, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8 Build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0003-4328-4843.
Elizaveta V. Stolyarova — student of the 6th course of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation.
Contact information: Kamilla K. Salamova, e-mail: kami_812@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 04.02.2021, revised 03.03.2021, accepted 29.03.2021.
2. Horn L.C., Schnurrbusch U., Bilek K. et. al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14(2):348–353. DOI: 10.1111/j.1048-891x.2004.014220.x.
3. Ngeow J., He X., Mester J.L. et. al. Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes. J Clin Endocrinol Metab. 2012;97(12):E2320–2327. DOI: 10.1210/jc.2012-2944.
4. Resta L., Cicinelli E., Lettini T. et al. Possible Inflammatory Origin of Endometrial Polyps. Arch Reprod Med Sexual Health. 2018;1:8–16.
5. Vishal C., Jong J.K., Doris M.B. et. al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):e8. DOI: 10.3802/jgo.2016.27.e8.
6. Dobrokhotova Yu.E., Litvinova N.A., Zadonskaya Yu.N. et al. The immunohystochemical characteristics as a criterion of efficiency of dydrogesterone therapy in patients with endometrial hyperplasia and uterine fibroid after uterine arteries embolization. Problems of reproduction. 2011;17(6):32–36 (in Russ.).
7. Pecorino B., Rubino C., Guardala V. et. al. Genetic screening in young women diagnosed with endometrial cancer. J Gynecol Oncol. 2017;28(1): e4. DOI: 10.3802/jgo.2017.28.e4.
8. Dobrokhotova Yu.E., Saprykina L.V. Treatment of recurrent endometrial hyperplasia in patients of premenopausal age. Farmateka. 2012;12:81–85 (in Russ.).
9. Zucchetto A., Serraino D., Polesel J. et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009;18:316–321. DOI: 10.1097/cej.0b013e328329d830.
10. Nordengren J., Pilka R., Noskova V. et al. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Mol Hum Reprod. 2004;10(9):655–663. DOI: 10.1093/molehr/gah081.
11. Ozolinja L.A., Lapina I.A. Rational approaches to the prevention of vascular complications in patients with endometrial hyperplastic processes. Gynecology. 2014;16:53–56 (in Russ.).
12. Mancuso A., De Vivo A., Fanara G. et al. Upper body venous thrombosis associated with ovarian stimulation: case report and review of the literature. Clin Exp Obstet Gynecol. 2005;32(3):149–154. PMID: 16433151.
13. Allahbadia G.N., ed. Intrauterine Insemination. Taylor and Francis; 2005.
14. Karateke A., Kaplanoglu M., Baloglu A. Relations of platelet indices with endometrial hyperplasia and endometrial cancer. Asian Pac J Cancer Prev. 2015;16(12):4905–4908. DOI: 10.7314/apjcp.2015.16.12.4905.
15. Novellas S., Chassang M., Delotte J. et al. MRI characteristics of the uterine junctional zone: from normal to the diagnosis of adenomyosis. AJR Am J Roentgenol. 2011;196(5):1206–1213. DOI: 10.2214/AJR.10.4877.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
